This study investigated the clinicopathological factors related with the efficacy and safety of T-DXd, with special attention to ILD, and suggested the appropriate management of T-DXd as third- or later-line treatment for patients with HER2-positive GC/GEJC. This evidence concerns the gene ERBB2 and gastric cancer.